Una S. Ryan

CIK: 0001255349

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RNXT

RenovoRx, Inc.

Director

QNCX

Quince Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

RNXT
RenovoRx, Inc.
Oct 1, 2026
Award(A)
Stock Options (right to buy)
Direct
55.9K shares-
RNXT
RenovoRx, Inc.
Oct 1, 2025
Award(A)
Stock Options (right to buy)
Direct
47.6K shares-
QNCX
Quince Therapeutics, Inc.
Jun 4, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
27K shares-
RNXT
RenovoRx, Inc.
Oct 1, 2024
Award(A)
Stock Options (right to buy)
Direct
25.1K shares-
RNXT
RenovoRx, Inc.
Apr 22, 2022
Other(J)
Indirect
16.2K shares at avg. $1.62$26K
RNXT
RenovoRx, Inc.
Apr 22, 2022
Other(J)
Indirect
26.8K shares at avg. $0.93$25K
RNXT
RenovoRx, Inc.
Mar 3, 2022
Other(J)
Indirect
6.3K shares at avg. $3.95$25K
RNXT
RenovoRx, Inc.
Mar 3, 2022
Other(J)
Indirect
47.8K shares at avg. $4.19$200K

		Type	Shares	Price		Ownership
Oct 1, 2026	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	55,924	-	-	Direct
Oct 1, 2025	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	47,640	-	-	Direct
Jun 4, 2025	QNCX Quince Therapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	27,000	-	-	Direct
Oct 1, 2024	RNXT RenovoRx, Inc.	Award(A) Stock Options (right to buy)	25,099	-	-	Direct
Apr 22, 2022	RNXT RenovoRx, Inc.	Other(J)	16,206	$1.62	$26,278	Indirect
Apr 22, 2022	RNXT RenovoRx, Inc.	Other(J)	26,838	$0.93	$25,000	Indirect
Mar 3, 2022	RNXT RenovoRx, Inc.	Other(J)	6,332	$3.95	$25,011	Indirect
Mar 3, 2022	RNXT RenovoRx, Inc.	Other(J)	47,789	$4.19	$200,236	Indirect

1-8 of 8 transactions

About RYAN UNA S

RYAN UNA S (SEC CIK 0001255349) files insider reports with the SEC as Director of RenovoRx, Inc. (RNXT) and Director of Quince Therapeutics, Inc. (QNCX).

Signal8 holds 5 ownership filings by RYAN UNA S, all Form 4s, filed between Oct 2, 2024 and Oct 2, 2026. Those filings report 8 transactions, from Mar 3, 2022 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on RYAN UNA S's filings is in MOUNTAIN VIEW, CA.

Recent filings by RYAN UNA S

Oct 1, 2026: Grant or award of RNXT derivative securities (Form 4, code A).
Oct 1, 2025: Grant or award of RNXT derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of QNCX derivative securities (Form 4, code A).
Oct 1, 2024: Grant or award of RNXT derivative securities (Form 4, code A).
Apr 22, 2022: Other transactions of RNXT shares (2 lines, Form 4, code J).

Other insiders filing for RenovoRx, Inc. (RNXT)

Macfarlane K. Angela, Director
Spiegel Robert J., Director
Marton Laurence, Director
VOLL MARK, Chief Financial Officer
Bagai Shaun, Chief Executive Officer
Gentry Leesa, Chief Clinical Officer

How to read Form 4 transaction codes